Acquired methemoglobinemia from multiple oxidants.
Phenazopyridine has been associated with methemoglobinemia in patients who have received an overdose, have decreased renal function, or are discovered to be unusually susceptible to the drug (ie, they may have an undetected NADH methemoglobin reductase deficiency). The case we have presented is unusual in that normal doses of phenazopyridine were given, no renal dysfunction was evident, and our patient had previously been given this drug without complication. Methemoglobinemia appeared to be the result of metabolic overload by multiple oxidants (phenazopyridine and lidocaine) of the normal reductase pathways in the erythrocytes. We saw no evidence to indicate that bupivacaine contributed to its development. Enzyme pathway changes induced by chemotherapy should be considered, though few studies have linked alterations of enzyme levels and pathways with chemotherapy and malignancy.
Conroy
J M
JM
Department of Anesthesiology, Medical University of South Carolina, Charleston 29425.
Baker
J D
JD
Martin
W J
WJ
Bailey
M K
MK
Dorman
B H
BH
D000287:Administration, Topical; D000328:Adult; D015360:Analgesia, Epidural; D001784:Blood Gas Analysis; D002045:Bupivacaine / Q000008:administration & dosage; D042966:Cytochrome-B(5) Reductase / Q000187:drug effects; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects*; D008708:Methemoglobinemia / Q000097:blood / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D010092:Oximetry; D010102:Oxygen Inhalation Therapy; D010146:Pain / Q000188:drug therapy; D010621:Phenazopyridine / Q000008:administration & dosage / Q000009:adverse effects*; D014555:Urination Disorders / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000503:physiopathology
D008012:Lidocaine; D042966:Cytochrome-B(5) Reductase; D010621:Phenazopyridine; D002045:Bupivacaine